Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Proffered Paper - SARS-CoV-2 and cancer 1

LBA71 - Systemic cancer treatment-related outcomes in patients with SARS-CoV-2 infection: A CCC19 registry analysis

Date

19 Sep 2020

Session

Proffered Paper - SARS-CoV-2 and cancer 1

Presenters

Trisha Wise-draper

Citation

Annals of Oncology (2020) 31 (suppl_4): S1142-S1215. 10.1016/annonc/annonc325

Authors

T.M. Wise-draper1, A. Desai2, A. Elkrief3, B.I. Rini4, D.B. Flora5, D.W. Bowles6, D. Shah7, D. Rivera8, D.B. Johnson4, G. Lopes9, P. Grivas10, M.A. Thompson11, S. Peters12, N.M. Kuderer13, N.L. Nock14, P. Grover15, X. Li16, S. Gulati15, T.K. Choueiri17, J. Warner4

Author affiliations

  • 1 Division Of Hematology/oncology, University of Cincinnati Cancer Center, 45267-0521 - Cincinnati/US
  • 2 Medicine, University of Connecticut, 06106 - Farmington/US
  • 3 Oncology, Segal Cancer Centre, Jewish General Hospital, McGill University, H2X 0A9 - Montreal/CA
  • 4 Division Of Hematology/oncology, Vanderbilt University Medical Center, 37232 - Nashville/US
  • 5 Medical Oncology, St Elizabeth Healthcare, Edgewood/US
  • 6 Division Of Medical Oncology, University of Colorado, Aurora/US
  • 7 Population Health Sciences, Mays Cancer Center at UT Health San Antonio MD Anderson, 78229 - San Antonio/US
  • 8 Division Of Cancer Control And Population Sciences, National Cancer Institute, 20850 - Rockville/US
  • 9 Oncology, University of Miami/Sylvester Comprehensive Cancer Center, 33146 - Miami/US
  • 10 Hematology Oncology, University of Washington Seattle Cancer Care Alliance, 98109-4405 - Seattle/US
  • 11 Aurora Cancer Care, Advocate Aurora Health, 53215 - Milwaukee/US
  • 12 Multidisciplinary Oncology Center, Centre Hospitalier Universitaire Vaudois - CHUV, 1011 - Lausanne/CH
  • 13 Medical Oncology, Advanced Cancer Research Group, Seattle/US
  • 14 Population And Quantitative Health Sciences, Case Comprehensive Cancer, CenterCase Western Reserve University, Cleveland/US
  • 15 Division Of Hematology/oncology, University of Cincinnati Cancer Center, Cincinnati/US
  • 16 Medicine, Vanderbilt University, 37232 - Nashville/US
  • 17 Medical Oncology Dept., Harvard Medical School, Dana Farber Cancer Institute, 2215 - Boston/US
More

Resources

Login to access the resources on OncologyPRO.

Abstract LBA71

Background

SARS-CoV-2 is associated with diverse clinical presentations ranging from asymptomatic infection to lethal complications. Small studies have suggested inferior outcomes in patients (pts) on active cancer treatment. This finding was not independently validated in our prior report on 928 pts, which included treatments administered within 4 weeks of COVID-19 diagnosis. Here, we examine outcomes related to systemic cancer treatment within one year of lab-confirmed SARS-CoV-2 infection in an expanded cohort.

Methods

The COVID-19 and Cancer Consortium (CCC19) registry (NCT04354701) was queried for pts ever receiving systemic treatment. Treatment type, cancer type, stage, and COVID-19 outcomes were examined. Pts were stratified by time from last treatment administration: <2 wk, 2-4 wk, 1-3 mo, or 3-12 mo. Standardized incidence ratios (SIR) of mortality by treatment type and timing were calculated.

Results

As of 31 July 2020, we analyzed 3920 pts; 42% received systemic anti-cancer treatment within 12 mo (Table). 159 distinct medications were administered. The highest rate of COVID-19-associated complications were observed in pts treated within 1-3 months prior to COVID-19; all-cause mortality in this group was 26%. 30-day mortality by most recent treatment type was 20% for chemotherapy, 18% for immunotherapy, 17% for chemoradiotherapy, 29% for chemoimmunotherapy, 20% for targeted therapy, and 11% for endocrine therapy. SIR of mortality was highest for chemoimmunotherapy or chemotherapy <2 wks, and lowest for endocrine treatments. A high SIR was also found for targeted agents within 3-12 mo. Pts untreated in the year prior to COVID-19 diagnosis had a mortality of 14%. Table: LBA71

Most recent treatment before COVID-19
<2 wk 2-4 wk 1-3 mo 3-12 mo
Total, n 915 298 230 143
Total deaths, % 16 16 26 17
Treatment Type, %
Chemo 30 46 44 45
Immuno (IO) 7 18 8 10
Chemo-IO 2 6 4 *
Targeted 39 32 35 25
Endocrine 32 13 19 14
Cancer Type, %
Solid tumor 63 68 63 59
Hematologic 26 18 24 25
Complications, %
Hospitalized 54 54 61 57
O2 required 41 43 45 41
ICU 14 16 17 13
Mech. ventilation 10 11 13 10
SIR Mortality (95% CI)
Chemo 1.31 (1.00-1.69) 1.18 (0.77-1.73) 0.92 (0.59-1.36) 0.92 (0.44-1.69)
IO 1.03 (0.51-1.85) 1.02 (0.46-1.93) * *
Chemo-IO 2.22 (0.95-4.37) * * *
Targeted 0.98 (0.74-1.27) 0.97 (0.54-1.60) 1.41 (0.95-2.03) 2.15 (1.14-3.68)
Endocrine 0.62 (0.42-0.88) * 0.73 (0.31-1.43) *

*Absolute number of pts <5.

Conclusions

30-day mortality was highest amongst cancer pts treated 1-3 months prior to COVID-19 diagnosis and those treated with chemoimmunotherapy. Except for endocrine therapy, mortality for subgroups was numerically higher than in pts untreated within a year prior to COVID-19 diagnosis.

Clinical trial identification

NCT04354701.

Editorial acknowledgement

Legal entity responsible for the study

The COVID-19 and Cancer Consortium (CCC19).

Funding

National Cancer Institute (P30 CA068485).

Disclosure

T.M. Wise-Draper: Research grant/Funding (self), Travel/Accommodation/Expenses: AstraZeneca; Research grant/Funding (self): BMS; Research grant/Funding (self): Tesaro/GSK; Advisory/Consultancy: Shattuck Labs; Leadership role, Travel/Accommodation/Expenses, HNC POA Lead: Caris Life Sciences; Research grant/Funding (self), Travel/Accommodation/Expenses: Merck; Travel/Accommodation/Expenses: Eli Lilly; Travel/Accommodation/Expenses: Bexion. A. Elkrief: Research grant/Funding (self): AstraZeneca. B.I. Rini: Advisory/Consultancy, Research grant/Funding (self), Travel/Accommodation/Expenses: Merck; Advisory/Consultancy, Research grant/Funding (self): Roche; Advisory/Consultancy, Research grant/Funding (self), Travel/Accommodation/Expenses: Pfizer; Advisory/Consultancy, Research grant/Funding (self): AVEO; Advisory/Consultancy, Research grant/Funding (self), Travel/Accommodation/Expenses: BMS; Advisory/Consultancy: arravive; Advisory/Consultancy: 3D medicines; Advisory/Consultancy: Synthorx; Advisory/Consultancy: Surface Oncology; Shareholder/Stockholder/Stock options: PTC Therapeutics; Research grant/Funding (self): AstraZeneca. D.B. Johnson: Advisory/Consultancy: Array Biopharma; Advisory/Consultancy, Research grant/Funding (self): BMS; Advisory/Consultancy: Janssen; Advisory/Consultancy: Merck; Advisory/Consultancy: Novartis; Research grant/Funding (self): Incyte; Leadership role: ASCO melanoma scientific committee chair; Leadership role: NCCN Melanoma committee. G. Lopes: Honoraria (self), Travel/Accommodation/Expenses: Boehringer Ingelheim; Advisory/Consultancy, Research grant/Funding (institution), Travel/Accommodation/Expenses: Pfizer; Advisory/Consultancy, Research grant/Funding (self), Research grant/Funding (institution): AstraZeneca; Research grant/Funding (institution): Merck; Research grant/Funding (institution): EMD Serono; Research grant/Funding (institution): Blueprint Medicine; Research grant/Funding (institution): Tesaro; Research grant/Funding (institution): Bavarian Nordic; Research grant/Funding (institution): Novartis; Research grant/Funding (institution): GI Therapeutics; Research grant/Funding (institution): adaptimmune; Research grant/Funding (institution): BMS; Research grant/Funding (institution): GSK; Research grant/Funding (institution): AbbVie; Research grant/Funding (institution): Rgenix; Research grant/Funding (institution): Roche; Research grant/Funding (institution): Genentech; Research grant/Funding (institution): Lilly; Research grant/Funding (institution), Travel/Accommodation/Expenses: Janssen; Travel/Accommodation/Expenses: E.R. Squibb Sons LLC. P. Grivas: Honoraria (self), Advisory/Consultancy, Research grant/Funding (self): AstraZeneca; Honoraria (self), Advisory/Consultancy, Research grant/Funding (self): Bayer; Honoraria (self), Advisory/Consultancy, Speaker Bureau/Expert testimony, Research grant/Funding (self): BMS; Honoraria (self), Advisory/Consultancy, Research grant/Funding (self): Clovis Oncology; Honoraria (self), Advisory/Consultancy: Driver; Honoraria (self), Advisory/Consultancy: EMD Serono; Honoraria (self), Advisory/Consultancy: Exelixis; Honoraria (self), Advisory/Consultancy: Foundation Medicine; Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution): Genentech; Honoraria (self), Advisory/Consultancy: Genzyme; Honoraria (self), Advisory/Consultancy: GSK; Honoraria (self), Advisory/Consultancy: Heron Therapeutics; Honoraria (self), Advisory/Consultancy: Janssen; Honoraria (self), Advisory/Consultancy, Research grant/Funding (self): Merck; Honoraria (self), Advisory/Consultancy, Research grant/Funding (self): Mirati Therapeutics; Honoraria (self), Advisory/Consultancy, Research grant/Funding (self): Pfizer; Honoraria (self), Advisory/Consultancy: Roche; Honoraria (self), Advisory/Consultancy: Seattle Genetics; Honoraria (self), Advisory/Consultancy: QED Therapeutics; Honoraria (institution): KureIT; Research grant/Funding (self): Bavarian Nordic; Research grant/Funding (self): Debiopharm; Research grant/Funding (self): Immunomedics; Research grant/Funding (self): Oncogenex. M.A. Thompson: Honoraria (self): AbbVie; Honoraria (self): BMS; Honoraria (self): Crab CTC; Honoraria (self): Denovo; Honoraria (self): Hoosier Research Network; Honoraria (self): Lilly; Honoraria (self): LynxBio; Honoraria (self): Strata Oncology; Honoraria (self), Advisory/Consultancy: Takeda; Honoraria (self): TG Therapeutics; Advisory/Consultancy: Adaptive; Advisory/Consultancy: AIM Specialty Health; Advisory/Consultancy: Cellgene (BMS); Advisory/Consultancy: GSK; Advisory/Consultancy: Via Oncology; Travel/Accommodation/Expenses, Shareholder/Stockholder/Stock options: Doximity; Travel/Accommodation/Expenses: Syapse; Licensing/Royalties: Uptodate. S. Peters: Honoraria (self), Honoraria (institution), Advisory/Consultancy: AbbVie; Honoraria (self), Honoraria (institution), Advisory/Consultancy, Research grant/Funding (self): Amgen; Honoraria (self), Honoraria (institution), Advisory/Consultancy, Research grant/Funding (self), Travel/Accommodation/Expenses: AstraZeneca; Honoraria (self), Honoraria (institution), Advisory/Consultancy: Bayer; Honoraria (self), Honoraria (institution), Advisory/Consultancy: Biocartis; Honoraria (self), Honoraria (institution), Advisory/Consultancy: Bioinvent; Honoraria (self), Honoraria (institution), Advisory/Consultancy: Blueprint Medicines; Honoraria (self), Honoraria (institution), Advisory/Consultancy, Research grant/Funding (self): Boehringer-Ingelheim; Honoraria (self), Honoraria (institution), Advisory/Consultancy, Research grant/Funding (self), Travel/Accommodation/Expenses: Bristol-Myers Squibb; Honoraria (self), Honoraria (institution), Advisory/Consultancy, Research grant/Funding (self): Clovis; Honoraria (self), Honoraria (institution), Advisory/Consultancy, Travel/Accommodation/Expenses: Daiichi Sankyo; Honoraria (self), Honoraria (institution), Advisory/Consultancy: Debiopharm; Honoraria (self), Honoraria (institution), Advisory/Consultancy: Eli Lilly; Honoraria (self), Honoraria (institution), Advisory/Consultancy, Research grant/Funding (self), Travel/Accommodation/Expenses: F. Hoffmann-La Roche; Honoraria (self), Honoraria (institution), Advisory/Consultancy: Foundation Medicine; Honoraria (self), Honoraria (institution), Advisory/Consultancy, Research grant/Funding (self), Travel/Accommodation/Expenses: Ilumina; Honoraria (self), Honoraria (institution), Advisory/Consultancy: Janssen; Honoraria (self), Honoraria (institution), Advisory/Consultancy, Research grant/Funding (self), Travel/Accommodation/Expenses: Merck Sharp and Dohme; Honoraria (self), Honoraria (institution), Advisory/Consultancy, Research grant/Funding (self): Merck Serono; Honoraria (self), Honoraria (institution), Advisory/Consultancy: Merrimack; Honoraria (self), Honoraria (institution), Advisory/Consultancy, Research grant/Funding (self): Novartis; Honoraria (self), Honoraria (institution), Advisory/Consultancy: PharmaMar; Honoraria (self), Honoraria (institution), Advisory/Consultancy, Research grant/Funding (self): Pfizer; Honoraria (self), Honoraria (institution), Advisory/Consultancy: Regeneron; Honoraria (self), Honoraria (institution), Advisory/Consultancy: Sanofi; Honoraria (self), Honoraria (institution), Advisory/Consultancy, Travel/Accommodation/Expenses: Seattle Genetics; Honoraria (self), Honoraria (institution), Advisory/Consultancy: Takeda; Honoraria (self), Honoraria (institution), Advisory/Consultancy: Vaccibody; Research grant/Funding (self): Biodesix. N.M. Kuderer: Advisory/Consultancy, Travel/Accommodation/Expenses: BMS; Advisory/Consultancy, Travel/Accommodation/Expenses: Janssen; Honoraria (self), Advisory/Consultancy: Celldex; Honoraria (self), Advisory/Consultancy: Invitae; Honoraria (self), Advisory/Consultancy: Total Health; Honoraria (self), Advisory/Consultancy: Beyond Springs; Honoraria (self), Advisory/Consultancy: BAyer; Honoraria (self), Advisory/Consultancy: Spectrum Pharmaceuticals. S. Gulati: Advisory/Consultancy: Puma Biotechnology; Travel/Accommodation/Expenses: ASCO; Research grant/Funding (self): AstraZeneca; Research grant/Funding (self): IsoRay. T.K. Choueiri: Honoraria (self), Advisory/Consultancy, Research grant/Funding (self): AstraZeneca; Honoraria (self), Advisory/Consultancy, Research grant/Funding (self): Alexion; Honoraria (self), Advisory/Consultancy, Research grant/Funding (self): Bayer; Honoraria (self), Advisory/Consultancy, Research grant/Funding (self): BMS; Honoraria (self), Advisory/Consultancy, Research grant/Funding (self): Cerulean; Honoraria (self), Advisory/Consultancy, Research grant/Funding (self): Eisai; Honoraria (self), Advisory/Consultancy, Research grant/Funding (self): Foundation Medicine; Honoraria (self), Advisory/Consultancy, Research grant/Funding (self): Exelixis; Advisory/Consultancy, Research grant/Funding (self): Ipsen; Research grant/Funding (self): Tracon; Honoraria (self), Advisory/Consultancy, Research grant/Funding (self): Genentech; Honoraria (self), Advisory/Consultancy, Research grant/Funding (self): Roche; Honoraria (self), Advisory/Consultancy, Research grant/Funding (self): GSK; Honoraria (self), Advisory/Consultancy, Research grant/Funding (self): Lilly; Honoraria (self), Advisory/Consultancy, Research grant/Funding (self): Merck; Honoraria (self), Advisory/Consultancy, Research grant/Funding (self): Novartis; Honoraria (self), Advisory/Consultancy, Research grant/Funding (self): Peloton; Honoraria (self), Advisory/Consultancy, Research grant/Funding (self): Pfizer; Honoraria (self), Advisory/Consultancy, Research grant/Funding (self): Promethius Labs; Advisory/Consultancy, Research grant/Funding (self): Corvus; Research grant/Funding (self): Calithera; Honoraria (self), Advisory/Consultancy, Research grant/Funding (self): Analysis Group; Honoraria (self), Research grant/Funding (self): Sanofi/Aventis; Research grant/Funding (self): Takeda; Honoraria (self): EMD Serono; Honoraria (self): Navinata Healthcare; Honoraria (self), Advisory/Consultancy: NCCN; Honoraria (self): Michael J. Hennessy (MJH) Associates, Inc (Healthcare Communications Company with several brands such as OnClive, PeerView and PER); Honoraria (self): Research to Practice; Advisory/Consultancy: Tempus. J. Warner: Advisory/Consultancy: BM Watson Health; Advisory/Consultancy: westat; Leadership role, Shareholder/Stockholder/Stock options: HemOnc.org LLC; Travel/Accommodation/Expenses: American Society of Clinical Oncology. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings